Brief: CARsgen Therapeutics Says U.S. FDA Granted Regenerative Medicine Advanced Therapy Designation To CT041
10/01/2022 01:13
Jan 10 (Reuters) - CARsgen Therapeutics Holdings Ltd
2171.HK :
* U.S. FDA GRANTED REGENERATIVE MEDICINE ADVANCED THERAPY
DESIGNATION TO CT041
Source text for Eikon: ID:nHKS6ssDCT
Further company coverage: 2171.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CARsgen Therapeutics Holdings
See all newsBrief: Carsgen Therapeutics Says CT1190B Receives IND Clearance From NMPA For Relapsed/Refractory Large B-Cell Lymphoma
Brief: Carsgen Therapeutics Says CT0596 Receives IND Clearance From NMPA
Brief: Carsgen Therapeutics Approves Share Repurchase Plan For Up To 30.12 Million Shares
CARsgen Therapeutics climbs on board nod for share buyback
Brief: Carsgen Therapeutics Says NMPA Approves Satricabtagene Autoleucel For Advanced Gastric Cancer